Advanced search
1 file | 676.56 KB

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e

(2013) PLOS ONE. 8(3).
Author
Organization
Abstract
Background: Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use. Methodology/Principal Findings: We have developed a live attenuated Bordetella pertussis vaccine, called BPZE1, and show here that it can be used to present the universal influenza virus epitope M2e to the mouse respiratory tract to prime for protective immunity against viral challenge. Three copies of M2e were genetically fused to the N-terminal domain of filamentous hemagglutinin (FHA) and produced in recombinant BPZE1 derivatives in the presence or absence of endogenous full-length FHA. Only in the absence of FHA intranasal administration of the recombinant BPZE1 derivative induced antibody responses to M2e and effectively primed BALB/c mice for protection against influenza virus-induced mortality and reduced the viral load after challenge. Strong M2e-specific antibody responses and protection were observed after a single nasal administration with the recombinant BPZE1 derivative, followed by a single administration of M2e linked to a virus-like particle without adjuvant, whereas priming alone with the vaccine strain did not protect. Conclusions/Significance: Using recombinant FHA-3M2e-producing BPZE1 derivatives for priming and the universal influenza M2e peptide linked to virus-like particles for boosting may constitute a promising approach for needle-free and adjuvant-free nasal vaccination against influenza.
Keywords
RECOMBINANT BORDETELLA-PERTUSSIS, GRAM-NEGATIVE BACTERIA, SEQUENCE, ADHERENCE, PROTECTION, IMMUNITY, INFECTION, STRAIN BPZE1, A VACCINE, FILAMENTOUS HEMAGGLUTININ

Downloads

  • 2197 13Kammoun.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 676.56 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Kammoun, Hana, Xavier Roux, Dominique Raze, Anne-Sophie Debrie, Marina De Filette, Tine Ysenbaert, Nathalie Mielcarek, Xavier Saelens, Walter Fiers, and Camille Locht. 2013. “Immunogenicity of Live Attenuated B. Pertussis BPZE1 Producing the Universal Influenza Vaccine Candidate M2e.” Plos One 8 (3).
APA
Kammoun, H., Roux, X., Raze, D., Debrie, A.-S., De Filette, M., Ysenbaert, T., Mielcarek, N., et al. (2013). Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. PLOS ONE, 8(3).
Vancouver
1.
Kammoun H, Roux X, Raze D, Debrie A-S, De Filette M, Ysenbaert T, et al. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. PLOS ONE. 2013;8(3).
MLA
Kammoun, Hana et al. “Immunogenicity of Live Attenuated B. Pertussis BPZE1 Producing the Universal Influenza Vaccine Candidate M2e.” PLOS ONE 8.3 (2013): n. pag. Print.
@article{3214548,
  abstract     = {Background: Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use.
Methodology/Principal Findings: We have developed a live attenuated Bordetella pertussis vaccine, called BPZE1, and show here that it can be used to present the universal influenza virus epitope M2e to the mouse respiratory tract to prime for protective immunity against viral challenge. Three copies of M2e were genetically fused to the N-terminal domain of filamentous hemagglutinin (FHA) and produced in recombinant BPZE1 derivatives in the presence or absence of endogenous full-length FHA. Only in the absence of FHA intranasal administration of the recombinant BPZE1 derivative induced antibody responses to M2e and effectively primed BALB/c mice for protection against influenza virus-induced mortality and reduced the viral load after challenge. Strong M2e-specific antibody responses and protection were observed after a single nasal administration with the recombinant BPZE1 derivative, followed by a single administration of M2e linked to a virus-like particle without adjuvant, whereas priming alone with the vaccine strain did not protect.
Conclusions/Significance: Using recombinant FHA-3M2e-producing BPZE1 derivatives for priming and the universal influenza M2e peptide linked to virus-like particles for boosting may constitute a promising approach for needle-free and adjuvant-free nasal vaccination against influenza.},
  articleno    = {e59198},
  author       = {Kammoun, Hana and Roux, Xavier and Raze, Dominique and Debrie, Anne-Sophie and De Filette, Marina and Ysenbaert, Tine and Mielcarek, Nathalie and Saelens, Xavier and Fiers, Walter and Locht, Camille},
  issn         = {1932-6203},
  journal      = {PLOS ONE},
  keywords     = {RECOMBINANT BORDETELLA-PERTUSSIS,GRAM-NEGATIVE BACTERIA,SEQUENCE,ADHERENCE,PROTECTION,IMMUNITY,INFECTION,STRAIN BPZE1,A VACCINE,FILAMENTOUS HEMAGGLUTININ},
  language     = {eng},
  number       = {3},
  pages        = {9},
  title        = {Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e},
  url          = {http://dx.doi.org/10.1371/journal.pone.0059198},
  volume       = {8},
  year         = {2013},
}

Altmetric
View in Altmetric
Web of Science
Times cited: